drugset / Trial / NCT00063778

Safety of an HIV Vaccine (AVX101) in HIV Uninfected Volunteers in the United States and South Africa

NCT00063778 ↗

RandomizedParallel-groupQuadruple-blindPrevention

Summary

The purpose of this study is to see if different doses of an experimental HIV vaccine are safe and to study how the immune system responds to the vaccine. The vaccine will be tested in healthy, HIV uninfected volunteers. AVX101 contains only one of the many substances that HIV needs to make more copies of itself; therefore, the vaccine cannot cause HIV or AIDS.

Timeline

Start
2003-07
Primary completion
2005-07
Completion
2005-07

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject AVX101 Vaccine 10000 iu Subcutaneous
Subject AVX101 Vaccine 100000 iu Subcutaneous